Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.52 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.47 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 1/20 | 0.44 |
| ▸ | HTR3B known ✓ | O95264 | 1/20 | 0.44 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.44 |
| ▸ | HTR3D known ✓ | Q70Z44 | 1/20 | 0.44 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 1/20 | 0.44 |
| ▸ | F7 | P08709 | 2/20 | 0.61 |
| ▸ | F3 | P13726 | 2/20 | 0.61 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.61 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.61 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.61 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.61 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.61 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.61 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1435906 | 1.00 | F7 (0.61) | F7F3SARM1SIRT2SIRT6 | |
| Hydrochloric Acid SCHEMBL5730267 | 1.00 | F7 (0.61) | F7F3SARM1SIRT2SIRT6 | |
| SCHEMBL415017 | 0.98 | — | — | |
| SCHEMBL31404951 | 0.98 | — | — | |
| Hydrochloric Acid SCHEMBL23497838 | 0.96 | F7 (0.61) | F7F3SARM1SIRT2SIRT6 | |
| Formic Acid SCHEMBL27094898 | 0.88 | F7 (0.58) | F7F3SARM1SIRT2SIRT6 | |
| Acetic Acid SCHEMBL4762786 | 0.87 | F7 (0.61) | F7F3SARM1SIRT2SIRT6 | |
| Hydrochloric Acid SCHEMBL3226020 | 0.85 | F7 (0.46) | F7F3SARM1SIRT2SIRT6 | |
| Pivalate SCHEMBL28025381 | 0.82 | F7 (0.56) | F7F3SARM1SIRT2SIRT6 | |
| Niacinamide SCHEMBL472893 | 0.81 | F7 (0.92) | F7F3SARM1SIRT2SIRT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 263 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117926289-A | Method for electrochemically synthesizing N-sulfoamidine derivatives under mild condition | 湘潭大学 | 2024-04-26 | — | — | CN | claimed |
| CN-116947854-A | Preparation method of imidazo [2,1-a ] isoquinoline compound | 赣南师范大学 | 2023-10-27 | — | — | CN | claimed |
| CN-102953080-B | From containing the method reclaiming tellurium cadmium telluride assembly | GENERAL ELECTRIC COMPANY (US) | 2015-08-05 | — | — | CN | claimed |
| CN-104177298-A | 4, 4-disubstituted-4, 5-dihydro-1H-imidazole-5-one and derivatives thereof as well as synthesis method thereof | UNIV XIANGTAN | 2014-12-03 | — | — | CN | claimed |
| CN-102953080-A | Method for recovering tellurium from component containing cadmium telluride | GEN ELECTRIC | 2013-03-06 | — | — | CN | claimed |
| EP-3883577-B1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | UNIV CASE WESTERN RESERVE (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20250304597-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2025-10-02 | — | — | US | disclosed |
| US-20250270201-A1 | SUBSTITUTED PYRIMIDINYL HYDRAZIDE COMPOUND AND PREPARATION METHOD AND USE THEREOF | ARIGENX THERAPEUTICS CO., LTD. (CN) | 2025-08-28 | — | — | US | disclosed |
| US-12336982-B2 | Compositions and methods of modulating short-chain dehydrogenase activity | RODEO THERAPEUTICS CORPORATION (US) | 2025-06-24 | — | — | US | disclosed |
| CN-120166906-A | Two-dimensional/three-dimensional perovskite heterojunction based on amidino cation and application of perovskite heterojunction in solar cell | 西安交通大学 | 2025-06-17 | — | — | CN | disclosed |
| CN-113507931-B | Compositions and methods for modulating short-chain dehydrogenase activity | 卡斯西部储备大学 | 2025-05-27 | — | — | CN | disclosed |
| US-20250161277-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2025-05-22 | — | — | US | disclosed |
| US-5541187-A | HYPOTENSIVE AGENTS | STERLING WINTHROP INC. (US) | 1996-07-30 | — | — | US | disclosed |
| US-5294612-A | Hypotensive agents and cardiovascular disorders | STERLING WINTHROP INC. (US) | 1994-03-15 | — | — | US | disclosed |
| US-5292740-A | Sulfonamides | HOFFMANN-LA ROCHE INC. (US) | 1994-03-08 | — | — | US | disclosed |
| EP-0526708-A1 | Sulfonamide, preparation and use thereof as medicine and intermediate | F. HOFFMANN-LA ROCHE AG (CH) | 1993-02-10 | — | — | EP | disclosed |
| US-5120861-A | DIAZIRINE DERIVATIVES OF AROMATIC HETEROCYCLIC COMPOUNDS | SHELL RESEARCH LIMITED (GB) | 1992-06-09 | — | — | US | disclosed |
| EP-0455356-A1 | Substituted 5-amino-1,2,4-thiadiazoles with pharmaceutical activity | LILLY INDUSTRIES LIMITED (GB) | 1991-11-06 | — | — | EP | disclosed |
| EP-0432817-A1 | Diazirine derivatives of aromatic heterocyclic compounds | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1991-06-19 | — | — | EP | disclosed |
| US-4109092-A | FROM PYRIDINYL-CARBOXAMIDINE AND ALPHA-CHLOROACRYLONITRILE | STERLING DRUG INC. (US) | 1978-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304597-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | HPGD, GCDH, HPGDS | GAA 420/4885HDAC1 699/4885HDAC6 1221/4885 |
| US-20250161277-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | HPGD, GCDH, HPGDS | GAA 420/4885HDAC1 699/4885HDAC6 1221/4885 |
| US-12336982-B2 | Compositions and methods of modulating short-chain dehydrogenase activity | HPGD, GCDH, HPGDS | GAA 420/4885HDAC1 699/4885HDAC6 1221/4885 |
| US-20250270201-A1 | SUBSTITUTED PYRIMIDINYL HYDRAZIDE COMPOUND AND PREPARATION METHOD AND USE THEREOF | AHR, ARNT, PAH | GAA 4102/4885HDAC1 1061/4885HDAC6 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.